UCB UCB remains focused on expanding its addressable patient population and developing its pipeline as the company continues to face generic competition. UCB received positive opinions from the ...

UCB's current portfolio faces key patent losses over the next 10 years, but successful pipeline development could help the firm offset the negative impact of generic competition. Among UCB's ...

Also in the phase III pipeline is epilepsy treatment brivaracetam. The drug is closely related to UCB's existing Keppra, but mouse studies suggested it was 10 times more potent in preventing ...

Brussels (Belgium), 23rd July 2014 – 0700 (CEST) – regulated information – UCB today announced an important advance in its research and development pipeline with positive topline results ...

UCB’s robust pipeline, built with partners is important as it allows us to maximize our collective resources and expertise which in turn will see us enter a new era of productivity for the ...

UCB pipeline estimates 'leave risks to the upside' - Citi View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 ...

BRUSSELS and SAN FRANCISCO, May 19, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world's largest ...

The data will include clinical and real-world data, plus medical research from across UCB's pipeline programs. (PRNewsfoto/UCB, Inc.) Dr Dimitrios Bourikas, Global Medical Head of Epilepsy ...

Pipeline updates brought a mix of positive developments and delays. UCB announced favorable Phase 2 data for galvokimig, a bispecific targeting IL-17A, IL-17F, and IL-13 in atopic dermatitis, ...

The asset is not yet listed in UCB’s online pipeline, which currently only includes clinical-stage assets. The company also has another clinical candidate targeting Parkinson’s. The asset ...

Despite these cost pressures, the company's product pipeline, including Bimzelx, is anticipated to deliver significant returns. Reflecting investor optimism about Bimzelx's potential, UCB's shares ...

changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or ...